CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Efavirenz + 2 NRTIs +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00075907
NCT00075907Phase 3Completed
CompareCT.gov

A Comparative Trial of Protease-Containing and Protease-Sparing HAART Regimens in HIV-Infected Adolescents With an Evaluation of Therapeutic Drug Monitoring

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 13, 2004·Updated Oct 7, 2013

In Brief

A Phase 3 clinical trial evaluating Efavirenz + 2 NRTIs, Lopinavir/Ritonavir + 2 NRTIs, and 1 other intervention for HIV Infections. Completed, across 13 sites.

Detailed Summary

The purpose of this study is to compare the effectiveness of anti-HIV drug regimens with or without a protease inhibitor (PI) in HIV infected adolescents. It will also determine if monitoring drug levels and adjusting the dose as necessary improves the effectiveness of these regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 13, 2004
Enrollment StartJul 1, 2004
Study CompletionSep 1, 2006
TodayJul 2, 2026
Posted 22.5 years ago

Interventions

Efavirenz + 2 NRTIsdrug

Lopinavir/Ritonavir + 2 NRTIsdrug

Therapeutic Drug Monitoringprocedure